Effectiveness of Yoga and Combined Exercise in Female With Rheumatoid Arthritis: Randomized Controlled Trial

ABSTRACT Background Although exercise is beneficial for Rheumatoid Arthritis (RA), the comparative efficacy of different modalities for patients in clinical remission remains unclear. This study compared the short‐ and long‐term effects of yoga versus a combined exercise programme on pain, balance, mobility, fatigue, depression, and quality of life in females with RA in remission. Methods In this single‐blind, randomized controlled trial, 74 female participants were allocated to yoga ( n = 25), combined exercise ( n = 25), or a usual care control group ( n = 24). The intervention groups underwent an 8‐week supervised programme. Clinical assessments, including the Visual Analogue Scale (pain), Berg Balance Scale, Timed Up and Go Test, Beck Depression Inventory, Fatigue Severity Scale, and Short Form‐36, were conducted at baseline, post‐intervention (8 weeks), and follow‐up (20 weeks). Results Both intervention groups demonstrated significant improvements in all outcome measures compared with the control group at post‐treatment and follow‐up ( p < 0.05). Notably, the yoga group exhibited superior outcomes compared to the combined exercise group in reducing pain intensity (median reduction of 4.00 vs. 2.00 points; p < 0.001, η 2 = 0.724), as well as in physical function, balance, fatigue, depression, and quality of life at the 20‐week follow‐up. These benefits may be partly attributed to the incorporation of breathing and relaxation techniques inherent to yoga practice. Conclusions Both 8‐week yoga and combined exercise programs are effective in managing residual symptoms in females with RA in clinical remission. However, yoga appears to provide superior benefits in pain management and psychosocial well‐being, supporting its integration into multidisciplinary RA management protocols, particularly for addressing psychosocial burden in patients achieving remission. Trial Registration This study was retrospectively registered at NCT07072754 ( clinicaltrials.gov )